RxDoctor Payments Data

Stuart Nathan

Physician Assistant · Westland, MINPI 1407836869

Payments from drug & device makers

$9,705in general payments, 2019–2025

Across 564 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$851
  • AstraZeneca$688
  • Boehringer Ingelheim$597
  • Bayer$374
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,705 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$72,819
Medicare patients
182
Services billed
4,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin72$82,097
OzempicSemaglutide44$55,066
EliquisApixaban41$51,873
RybelsusSemaglutide22$35,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$34,060
XareltoRivaroxaban22$29,491
MounjaroTirzepatide20$23,818
EntrestoSacubitril/Valsartan16$15,609
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,685
Aimovig AutoinjectorErenumab-Aooe12$8,493
Humalog Kwikpen U-100Insulin Lispro15$3,606
Atorvastatin Calcium222$3,333
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,979
Arnuity ElliptaFluticasone Furoate11$2,890
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,140$90,13666 claims
Boehringer IngelheimJardiance$597$82,09772 claims
PfizerEliquis$262$51,87341 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$270$45,63456 claims
Johnson & JohnsonXarelto$159$29,49122 claims
Lilly USA, LLCMounjaro$1,499$23,81820 claims
NovartisEntresto$100$15,60916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Westland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →